| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastroplasty | 58 | 2020 | 63 | 14.880 |
Why?
|
| Obesity, Morbid | 51 | 2020 | 172 | 10.920 |
Why?
|
| Laparoscopy | 51 | 2020 | 237 | 7.870 |
Why?
|
| Weight Loss | 61 | 2020 | 319 | 7.810 |
Why?
|
| Obesity | 45 | 2018 | 1076 | 6.180 |
Why?
|
| Bariatric Surgery | 22 | 2019 | 90 | 4.500 |
Why?
|
| Diabetes Mellitus, Type 2 | 17 | 2019 | 1085 | 2.490 |
Why?
|
| Postoperative Complications | 14 | 2016 | 1615 | 1.610 |
Why?
|
| Metabolic Syndrome | 9 | 2018 | 191 | 1.420 |
Why?
|
| Middle Aged | 67 | 2019 | 21147 | 1.290 |
Why?
|
| Adult | 66 | 2019 | 21403 | 1.240 |
Why?
|
| Australia | 16 | 2021 | 235 | 1.180 |
Why?
|
| Treatment Outcome | 35 | 2019 | 7029 | 1.180 |
Why?
|
| Feeding Behavior | 7 | 2020 | 224 | 1.170 |
Why?
|
| Humans | 114 | 2021 | 68618 | 1.150 |
Why?
|
| Depression | 9 | 2012 | 943 | 1.120 |
Why?
|
| Female | 75 | 2019 | 38074 | 1.100 |
Why?
|
| Satiety Response | 4 | 2010 | 8 | 1.060 |
Why?
|
| Male | 70 | 2019 | 37321 | 1.040 |
Why?
|
| Gastric Bypass | 7 | 2013 | 83 | 0.980 |
Why?
|
| Patient Selection | 5 | 2012 | 592 | 0.970 |
Why?
|
| Quality of Life | 20 | 2018 | 1515 | 0.920 |
Why?
|
| Body Mass Index | 18 | 2018 | 867 | 0.910 |
Why?
|
| Fatty Liver | 5 | 2013 | 97 | 0.880 |
Why?
|
| Prospective Studies | 20 | 2018 | 3705 | 0.880 |
Why?
|
| Body Image | 4 | 2011 | 100 | 0.870 |
Why?
|
| Satiation | 4 | 2017 | 9 | 0.870 |
Why?
|
| Gastric Emptying | 3 | 2011 | 24 | 0.840 |
Why?
|
| Peristalsis | 3 | 2010 | 76 | 0.770 |
Why?
|
| Manometry | 7 | 2017 | 276 | 0.740 |
Why?
|
| Reoperation | 10 | 2019 | 467 | 0.740 |
Why?
|
| Diet, Reducing | 5 | 2012 | 46 | 0.730 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 4 | 2017 | 87 | 0.720 |
Why?
|
| Follow-Up Studies | 15 | 2018 | 3259 | 0.700 |
Why?
|
| Appetite Regulation | 3 | 2008 | 11 | 0.690 |
Why?
|
| Insulin | 7 | 2015 | 619 | 0.680 |
Why?
|
| Esophagus | 3 | 2010 | 303 | 0.680 |
Why?
|
| Body Composition | 3 | 2012 | 119 | 0.650 |
Why?
|
| Adipose Tissue | 3 | 2014 | 221 | 0.600 |
Why?
|
| Prostheses and Implants | 2 | 2011 | 159 | 0.580 |
Why?
|
| Pregnancy Complications | 3 | 2011 | 286 | 0.570 |
Why?
|
| Overweight | 2 | 2017 | 186 | 0.540 |
Why?
|
| Sleep Apnea, Obstructive | 6 | 2015 | 142 | 0.540 |
Why?
|
| Liver | 4 | 2014 | 1118 | 0.530 |
Why?
|
| Esophageal Sphincter, Lower | 3 | 2010 | 22 | 0.520 |
Why?
|
| Caloric Restriction | 2 | 2013 | 22 | 0.520 |
Why?
|
| Insulin-Secreting Cells | 1 | 2015 | 41 | 0.510 |
Why?
|
| Exercise | 3 | 2012 | 658 | 0.480 |
Why?
|
| Liver Cirrhosis | 4 | 2017 | 301 | 0.480 |
Why?
|
| Omentum | 1 | 2014 | 18 | 0.480 |
Why?
|
| Muscle, Skeletal | 5 | 2013 | 396 | 0.470 |
Why?
|
| Androgens | 1 | 2014 | 41 | 0.470 |
Why?
|
| Surveys and Questionnaires | 10 | 2016 | 2800 | 0.470 |
Why?
|
| Premenopause | 1 | 2014 | 57 | 0.470 |
Why?
|
| Patient Compliance | 4 | 2016 | 402 | 0.460 |
Why?
|
| Esophagogastric Junction | 3 | 2016 | 118 | 0.450 |
Why?
|
| Abdominal Fat | 2 | 2019 | 8 | 0.450 |
Why?
|
| Gastric Dilatation | 2 | 2014 | 3 | 0.430 |
Why?
|
| Adolescent | 13 | 2014 | 8912 | 0.430 |
Why?
|
| Time Factors | 10 | 2013 | 4655 | 0.420 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 67 | 0.420 |
Why?
|
| Motivation | 2 | 2009 | 561 | 0.420 |
Why?
|
| Esophageal Motility Disorders | 2 | 2009 | 59 | 0.410 |
Why?
|
| Blood Glucose | 8 | 2013 | 631 | 0.410 |
Why?
|
| Aged | 18 | 2016 | 14862 | 0.410 |
Why?
|
| Personality Inventory | 1 | 2012 | 197 | 0.400 |
Why?
|
| Device Removal | 4 | 2013 | 100 | 0.400 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 219 | 0.400 |
Why?
|
| Bariatrics | 3 | 2005 | 5 | 0.390 |
Why?
|
| Foreign-Body Migration | 1 | 2011 | 38 | 0.390 |
Why?
|
| Mood Disorders | 1 | 2012 | 132 | 0.380 |
Why?
|
| Gastrointestinal Transit | 1 | 2010 | 16 | 0.370 |
Why?
|
| Head and Neck Neoplasms | 3 | 2018 | 561 | 0.370 |
Why?
|
| Risk Factors | 11 | 2017 | 5731 | 0.370 |
Why?
|
| Life Style | 2 | 2010 | 338 | 0.370 |
Why?
|
| Appetite Depressants | 2 | 2007 | 11 | 0.360 |
Why?
|
| Stereotyping | 1 | 2010 | 20 | 0.350 |
Why?
|
| Prejudice | 1 | 2010 | 37 | 0.350 |
Why?
|
| Lactones | 2 | 2007 | 64 | 0.350 |
Why?
|
| Disclosure | 1 | 2010 | 45 | 0.350 |
Why?
|
| Conflict of Interest | 1 | 2010 | 48 | 0.350 |
Why?
|
| Health Status | 3 | 2010 | 429 | 0.340 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2009 | 782 | 0.330 |
Why?
|
| Leukocyte Count | 2 | 2006 | 94 | 0.330 |
Why?
|
| Pressure | 1 | 2009 | 252 | 0.330 |
Why?
|
| Perception | 1 | 2010 | 189 | 0.320 |
Why?
|
| Drug Therapy | 1 | 2009 | 71 | 0.320 |
Why?
|
| Adiposity | 2 | 2019 | 88 | 0.310 |
Why?
|
| Insulin Resistance | 5 | 2015 | 241 | 0.310 |
Why?
|
| Young Adult | 8 | 2016 | 5717 | 0.300 |
Why?
|
| Bulimia Nervosa | 1 | 2008 | 21 | 0.300 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 180 | 0.300 |
Why?
|
| Deglutition Disorders | 2 | 2017 | 297 | 0.300 |
Why?
|
| Body Weights and Measures | 1 | 2007 | 11 | 0.300 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2007 | 28 | 0.290 |
Why?
|
| Skinfold Thickness | 1 | 2007 | 11 | 0.290 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2007 | 17 | 0.290 |
Why?
|
| Polysomnography | 2 | 2007 | 92 | 0.280 |
Why?
|
| Health Status Indicators | 4 | 2010 | 117 | 0.280 |
Why?
|
| Transaminases | 1 | 2006 | 21 | 0.280 |
Why?
|
| Nutritional Sciences | 1 | 2006 | 21 | 0.280 |
Why?
|
| Alcohol Drinking | 2 | 2003 | 805 | 0.270 |
Why?
|
| Incidence | 4 | 2013 | 1603 | 0.270 |
Why?
|
| Electric Impedance | 1 | 2007 | 131 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2011 | 629 | 0.270 |
Why?
|
| Feeding and Eating Disorders | 1 | 2008 | 106 | 0.270 |
Why?
|
| Shoulder Pain | 1 | 2005 | 12 | 0.260 |
Why?
|
| Supine Position | 1 | 2005 | 11 | 0.260 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2005 | 32 | 0.250 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 157 | 0.250 |
Why?
|
| Fecal Incontinence | 1 | 2004 | 6 | 0.250 |
Why?
|
| Aftercare | 2 | 2016 | 114 | 0.240 |
Why?
|
| Anal Canal | 1 | 2004 | 28 | 0.240 |
Why?
|
| Education, Medical | 1 | 2006 | 147 | 0.240 |
Why?
|
| Anesthesia, General | 1 | 2005 | 86 | 0.240 |
Why?
|
| Preoperative Care | 1 | 2006 | 275 | 0.240 |
Why?
|
| Postoperative Period | 4 | 2017 | 238 | 0.240 |
Why?
|
| Cholesterol | 3 | 2018 | 331 | 0.230 |
Why?
|
| Fasting | 3 | 2013 | 75 | 0.230 |
Why?
|
| Retrospective Studies | 7 | 2018 | 7277 | 0.230 |
Why?
|
| Stress, Psychological | 3 | 2008 | 824 | 0.220 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2003 | 30 | 0.220 |
Why?
|
| Cholelithiasis | 1 | 2003 | 66 | 0.220 |
Why?
|
| Dietary Sucrose | 1 | 2002 | 18 | 0.210 |
Why?
|
| Research Design | 2 | 2017 | 729 | 0.210 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2003 | 40 | 0.210 |
Why?
|
| Stomach Diseases | 1 | 2002 | 22 | 0.210 |
Why?
|
| Zinostatin | 1 | 2002 | 2 | 0.210 |
Why?
|
| Maleic Anhydrides | 1 | 2002 | 3 | 0.210 |
Why?
|
| Liver Circulation | 1 | 2002 | 40 | 0.200 |
Why?
|
| Factor Analysis, Statistical | 3 | 2016 | 201 | 0.200 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2002 | 38 | 0.200 |
Why?
|
| Polystyrenes | 1 | 2002 | 20 | 0.200 |
Why?
|
| Receptors, Cell Surface | 3 | 2010 | 248 | 0.200 |
Why?
|
| Cohort Studies | 3 | 2016 | 2358 | 0.200 |
Why?
|
| Triglycerides | 4 | 2018 | 184 | 0.200 |
Why?
|
| Medical Marijuana | 1 | 2021 | 21 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 1465 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 384 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2002 | 123 | 0.190 |
Why?
|
| Lipids | 1 | 2002 | 298 | 0.180 |
Why?
|
| Alanine Transaminase | 4 | 2017 | 137 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2010 | 2007 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2010 | 2279 | 0.180 |
Why?
|
| Adipocytes | 2 | 2019 | 88 | 0.180 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 306 | 0.180 |
Why?
|
| Automobile Driving | 1 | 2021 | 88 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2011 | 1553 | 0.180 |
Why?
|
| Barium Sulfate | 2 | 2010 | 66 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 504 | 0.170 |
Why?
|
| Cannabis | 1 | 2021 | 115 | 0.170 |
Why?
|
| Subcutaneous Fat | 1 | 2019 | 5 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2003 | 940 | 0.160 |
Why?
|
| Cholesterol, HDL | 3 | 2004 | 112 | 0.160 |
Why?
|
| Silicones | 2 | 2011 | 32 | 0.160 |
Why?
|
| Fluoroscopy | 2 | 2009 | 152 | 0.160 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2013 | 126 | 0.160 |
Why?
|
| Biomarkers | 4 | 2013 | 1593 | 0.160 |
Why?
|
| Linear Models | 3 | 2004 | 521 | 0.150 |
Why?
|
| Aspartate Aminotransferases | 3 | 2015 | 87 | 0.150 |
Why?
|
| Sirolimus | 1 | 2018 | 118 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 118 | 0.150 |
Why?
|
| Remission Induction | 2 | 2015 | 111 | 0.150 |
Why?
|
| Cross-Over Studies | 2 | 2010 | 260 | 0.150 |
Why?
|
| Pregnancy | 3 | 2011 | 2334 | 0.140 |
Why?
|
| Deglutition | 2 | 2010 | 221 | 0.140 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2017 | 5 | 0.140 |
Why?
|
| Models, Economic | 1 | 2017 | 69 | 0.140 |
Why?
|
| Self Concept | 2 | 2010 | 132 | 0.140 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 1851 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2002 | 561 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 107 | 0.140 |
Why?
|
| Area Under Curve | 2 | 2017 | 238 | 0.140 |
Why?
|
| Hernia, Hiatal | 1 | 2016 | 18 | 0.140 |
Why?
|
| Leptin | 2 | 2006 | 80 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 468 | 0.130 |
Why?
|
| Adenylate Kinase | 2 | 2006 | 10 | 0.130 |
Why?
|
| Herniorrhaphy | 1 | 2016 | 38 | 0.130 |
Why?
|
| Anti-Obesity Agents | 2 | 2006 | 42 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2016 | 150 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 951 | 0.130 |
Why?
|
| Mandible | 1 | 2015 | 53 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 1 | 2017 | 318 | 0.120 |
Why?
|
| Anastomosis, Roux-en-Y | 2 | 2005 | 15 | 0.120 |
Why?
|
| gamma-Glutamyltransferase | 2 | 2006 | 37 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 2077 | 0.120 |
Why?
|
| Diabetes Mellitus | 3 | 2013 | 694 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 1753 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 1070 | 0.120 |
Why?
|
| Prevalence | 2 | 2013 | 1619 | 0.120 |
Why?
|
| Neutrophils | 2 | 2006 | 204 | 0.120 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 56 | 0.120 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2013 | 26 | 0.120 |
Why?
|
| Testosterone | 1 | 2014 | 96 | 0.110 |
Why?
|
| Comorbidity | 2 | 2009 | 1426 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2016 | 652 | 0.110 |
Why?
|
| ROC Curve | 2 | 2017 | 392 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2013 | 50 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2016 | 322 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 475 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2013 | 53 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 536 | 0.110 |
Why?
|
| Behavior Therapy | 2 | 2006 | 297 | 0.110 |
Why?
|
| TYK2 Kinase | 1 | 2012 | 1 | 0.110 |
Why?
|
| Registries | 1 | 2016 | 733 | 0.110 |
Why?
|
| Adipose Tissue, Brown | 1 | 2012 | 8 | 0.110 |
Why?
|
| Hypoglycemic Agents | 2 | 2014 | 362 | 0.110 |
Why?
|
| Age Distribution | 1 | 2013 | 320 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2014 | 330 | 0.100 |
Why?
|
| Lipase | 1 | 2012 | 16 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 86 | 0.100 |
Why?
|
| Cells, Cultured | 6 | 2019 | 2673 | 0.100 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2012 | 93 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 546 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2013 | 753 | 0.100 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2012 | 257 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 468 | 0.100 |
Why?
|
| Health Care Costs | 2 | 2017 | 346 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2011 | 83 | 0.100 |
Why?
|
| Mice | 6 | 2019 | 8474 | 0.090 |
Why?
|
| Phenotype | 1 | 2013 | 947 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 2010 | 166 | 0.090 |
Why?
|
| Gastrointestinal Motility | 1 | 2010 | 52 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 581 | 0.090 |
Why?
|
| Financial Support | 1 | 2010 | 5 | 0.090 |
Why?
|
| Mannose-Binding Lectins | 1 | 2010 | 8 | 0.090 |
Why?
|
| CD11c Antigen | 1 | 2010 | 18 | 0.090 |
Why?
|
| Inflammation | 2 | 2014 | 1030 | 0.090 |
Why?
|
| Logistic Models | 2 | 2005 | 1420 | 0.090 |
Why?
|
| Phosphorylation | 4 | 2018 | 1200 | 0.090 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 39 | 0.090 |
Why?
|
| Disease Progression | 1 | 2013 | 1038 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2011 | 231 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2018 | 2689 | 0.090 |
Why?
|
| Dilatation, Pathologic | 1 | 2009 | 58 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 378 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2011 | 737 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 792 | 0.080 |
Why?
|
| Muscle Contraction | 1 | 2010 | 210 | 0.080 |
Why?
|
| Focus Groups | 1 | 2010 | 247 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 438 | 0.080 |
Why?
|
| Age Factors | 2 | 2013 | 1864 | 0.080 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2009 | 106 | 0.080 |
Why?
|
| Video Recording | 1 | 2009 | 145 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 189 | 0.080 |
Why?
|
| Self-Help Groups | 1 | 2008 | 38 | 0.080 |
Why?
|
| Ceramides | 1 | 2011 | 578 | 0.070 |
Why?
|
| Cetuximab | 1 | 2007 | 19 | 0.070 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 83 | 0.070 |
Why?
|
| Health Surveys | 1 | 2009 | 489 | 0.070 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2006 | 1 | 0.070 |
Why?
|
| Intra-Abdominal Fat | 1 | 2006 | 11 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2010 | 1738 | 0.070 |
Why?
|
| Drug Design | 1 | 2007 | 107 | 0.070 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2006 | 12 | 0.070 |
Why?
|
| Liver Function Tests | 2 | 2017 | 114 | 0.070 |
Why?
|
| Macrophages | 1 | 2010 | 647 | 0.070 |
Why?
|
| Bone Density | 1 | 2007 | 159 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 151 | 0.070 |
Why?
|
| Anthropometry | 1 | 2006 | 64 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2009 | 448 | 0.070 |
Why?
|
| Biliopancreatic Diversion | 1 | 2005 | 3 | 0.070 |
Why?
|
| Energy Intake | 1 | 2006 | 123 | 0.060 |
Why?
|
| Stomach | 1 | 2005 | 80 | 0.060 |
Why?
|
| Blood Gas Analysis | 1 | 2005 | 41 | 0.060 |
Why?
|
| Animals | 6 | 2019 | 20881 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2008 | 622 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2006 | 228 | 0.060 |
Why?
|
| Permeability | 1 | 2005 | 131 | 0.060 |
Why?
|
| Equipment Failure Analysis | 1 | 2005 | 121 | 0.060 |
Why?
|
| Data Collection | 1 | 2006 | 420 | 0.060 |
Why?
|
| Body Size | 1 | 2004 | 39 | 0.060 |
Why?
|
| Weight Gain | 1 | 2005 | 135 | 0.060 |
Why?
|
| Fibrosis | 1 | 2006 | 371 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 511 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 447 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 146 | 0.060 |
Why?
|
| Exercise Therapy | 1 | 2006 | 183 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 258 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2005 | 222 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2005 | 171 | 0.060 |
Why?
|
| Health Behavior | 1 | 2008 | 458 | 0.060 |
Why?
|
| Gene Frequency | 1 | 2003 | 207 | 0.060 |
Why?
|
| Body Weight | 1 | 2005 | 554 | 0.050 |
Why?
|
| Cholecystectomy | 1 | 2003 | 79 | 0.050 |
Why?
|
| Biopsy | 2 | 2017 | 540 | 0.050 |
Why?
|
| Contraindications | 1 | 2002 | 52 | 0.050 |
Why?
|
| Hernia | 1 | 2002 | 13 | 0.050 |
Why?
|
| Equipment Design | 1 | 2004 | 500 | 0.050 |
Why?
|
| Wine | 1 | 2002 | 4 | 0.050 |
Why?
|
| Beer | 1 | 2002 | 6 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 301 | 0.050 |
Why?
|
| Curriculum | 1 | 2006 | 575 | 0.050 |
Why?
|
| Iodized Oil | 1 | 2002 | 2 | 0.050 |
Why?
|
| Corrosion Casting | 1 | 2002 | 2 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2005 | 955 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2003 | 216 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 129 | 0.050 |
Why?
|
| Microcirculation | 1 | 2002 | 77 | 0.050 |
Why?
|
| Mice, Inbred CBA | 1 | 2002 | 107 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2002 | 163 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1174 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2002 | 236 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2003 | 249 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2002 | 90 | 0.050 |
Why?
|
| Genotype | 1 | 2003 | 786 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2002 | 161 | 0.050 |
Why?
|
| Recurrence | 2 | 2016 | 948 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2002 | 87 | 0.050 |
Why?
|
| Necrosis | 1 | 2002 | 239 | 0.050 |
Why?
|
| Policy | 1 | 2021 | 58 | 0.050 |
Why?
|
| Algorithms | 1 | 2007 | 1196 | 0.050 |
Why?
|
| Homeostasis | 1 | 2002 | 291 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1293 | 0.050 |
Why?
|
| Sleep Wake Disorders | 1 | 2002 | 94 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 183 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2005 | 445 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2002 | 295 | 0.040 |
Why?
|
| Hunger | 1 | 2020 | 27 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2019 | 75 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 18 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1174 | 0.040 |
Why?
|
| Asthma | 1 | 2002 | 345 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 38 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 238 | 0.040 |
Why?
|
| Proteome | 1 | 2019 | 87 | 0.040 |
Why?
|
| Contrast Media | 1 | 2002 | 595 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 104 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 304 | 0.040 |
Why?
|
| United States | 2 | 2017 | 7367 | 0.040 |
Why?
|
| Lipoproteins, HDL | 1 | 2018 | 113 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2006 | 1664 | 0.040 |
Why?
|
| Transcriptome | 1 | 2019 | 164 | 0.040 |
Why?
|
| Esophageal pH Monitoring | 1 | 2017 | 27 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 2223 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2018 | 98 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2006 | 20 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 710 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 331 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 193 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 2324 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 800 | 0.030 |
Why?
|
| Receptors, Adiponectin | 2 | 2006 | 10 | 0.030 |
Why?
|
| Adiponectin | 2 | 2006 | 52 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2018 | 343 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 208 | 0.030 |
Why?
|
| Cephalometry | 1 | 2015 | 19 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 206 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2015 | 98 | 0.030 |
Why?
|
| Patient Safety | 1 | 2016 | 202 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 756 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Palliative Care | 1 | 2016 | 271 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 32 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2006 | 791 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1851 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2013 | 10 | 0.030 |
Why?
|
| Myogenin | 1 | 2013 | 9 | 0.030 |
Why?
|
| Myostatin | 1 | 2013 | 9 | 0.030 |
Why?
|
| Keratin-7 | 1 | 2013 | 2 | 0.030 |
Why?
|
| MyoD Protein | 1 | 2013 | 13 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2013 | 14 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2013 | 33 | 0.030 |
Why?
|
| Missouri | 1 | 2013 | 44 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2013 | 42 | 0.030 |
Why?
|
| Muscular Atrophy | 1 | 2013 | 35 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 931 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2013 | 94 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 77 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 254 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 196 | 0.030 |
Why?
|
| Lipolysis | 1 | 2012 | 13 | 0.030 |
Why?
|
| Hypertension | 1 | 2002 | 1535 | 0.030 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2012 | 33 | 0.030 |
Why?
|
| RNA | 1 | 2013 | 171 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 236 | 0.020 |
Why?
|
| Apoptosis | 1 | 2018 | 1641 | 0.020 |
Why?
|
| Proteomics | 1 | 2013 | 246 | 0.020 |
Why?
|
| Stem Cells | 1 | 2013 | 248 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 492 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1027 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 489 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 320 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 700 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 1034 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1692 | 0.020 |
Why?
|
| Glucose | 1 | 2010 | 307 | 0.020 |
Why?
|
| Victoria | 1 | 2007 | 8 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1040 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2006 | 6 | 0.020 |
Why?
|
| Cause of Death | 1 | 2007 | 241 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2006 | 12 | 0.020 |
Why?
|
| Ribonucleotides | 1 | 2006 | 26 | 0.020 |
Why?
|
| Palmitates | 1 | 2006 | 20 | 0.020 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2006 | 25 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 174 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 2550 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 3187 | 0.020 |
Why?
|
| Survival Rate | 1 | 2007 | 1056 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2005 | 567 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 562 | 0.010 |
Why?
|
| Prognosis | 1 | 2007 | 2093 | 0.010 |
Why?
|
| Child | 1 | 2013 | 6405 | 0.010 |
Why?
|
| Diet | 1 | 2002 | 514 | 0.010 |
Why?
|